相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Martin R. Gaudinski et al.
LANCET (2018)
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial
Katherine Houser et al.
PLOS ONE (2018)
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season
Lisa A. Grohskopf et al.
MMWR RECOMMENDATIONS AND REPORTS (2018)
A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control
Riju Ray et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
Adam D. DeZure et al.
NPJ VACCINES (2017)
2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type
Richard K. Zimmerman et al.
CLINICAL INFECTIOUS DISEASES (2016)
Influenza Vaccines: Challenges and Solutions
Katherine Houser et al.
CELL HOST & MICROBE (2015)
Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost
Julie E. Ledgerwood et al.
CONTEMPORARY CLINICAL TRIALS (2015)
Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
Michelle C. Crank et al.
PLOS ONE (2015)
DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial
Julie E. Ledgerwood et al.
PLOS ONE (2015)
Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States
Carrie Reed et al.
PLOS ONE (2015)
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
Carlos A. DiazGranados et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial
Peter Tsang et al.
VACCINE (2014)
Seasonal influenza vaccine dose distribution in 157 countries (2004-2011)
Abraham Palache et al.
VACCINE (2014)
A Meta-analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events
Fawziah Marra et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2013)
Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect
Julie E. Ledgerwood et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age
Geoffrey J. Gorse et al.
VACCINE (2013)
Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age
Geoffrey J. Gorse et al.
VACCINE (2013)
Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans
J. E. Ledgerwood et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch
Yeu-Chun Kim et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2012)
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Michael T. Osterholm et al.
LANCET INFECTIOUS DISEASES (2012)
DNA Vaccination in the Skin Using Microneedles Improves Protection Against Influenza
Jae-Min Song et al.
MOLECULAR THERAPY (2012)
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
Julie E. Ledgerwood et al.
LANCET INFECTIOUS DISEASES (2011)
A systematic review of intradermal influenza vaccines
Flora Young et al.
VACCINE (2011)
Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults
Robert W. Frenck et al.
VACCINE (2011)
DNA vaccines A safe and efficient platform technology for responding to emerging infectious diseases
Julie E. Ledgerwood et al.
HUMAN VACCINES (2009)
Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older
Ann R. Falsey et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Better influenza vaccines for older people: What will it take?
Janet E. McElhaney et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
Julie E. Martin et al.
VACCINE (2008)
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial
Julie E. Martin et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
The annual impact of seasonal influenza in the US: Measuring disease burden and costs
Noelle-Angelique M. Molinari et al.
VACCINE (2007)
Influenza- and RSV-associated hospitalizations among adults
John P. Mullooly et al.
VACCINE (2007)
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
Barney S. Graham et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
Julie E. Martin et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
T cell responses are better correlates of vaccine protection in the elderly
JE McElhaney et al.
JOURNAL OF IMMUNOLOGY (2006)
分享论文
